FDA Launches Expedited IND Pilot Under Operation TrialBlazer
Start here
The FDA has launched the Expedited IND Pilot Program under HHS Operation TrialBlazer, aiming to shorten the path from IND-enabling activities to first-in-human trials in the US. Sponsors that voluntarily partner with qualified research institutions can submit IND components — toxicology, clinical and CMC — for rolling FDA review through the ESG gateway during the pre-IND phase, rather than waiting for a complete package. A Qualified Research Initiative reviews each discipline-specific component and flags issues that could trigger a clinical hold. Most activity occurs before the official 30-day IND application, with sponsors and QRIs setting the submission sequence and timeline and providing written and verbal feedback throughout. FDA retains full regulatory authority, and the pilot's evidence may shape future policy, such as accreditation of these institutions.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- fda.govExpedited IND Rolling Submission Process and Program Structure
FDA has detailed how its Expedited IND Pilot will work, with most activity occurring during the pre-IND phase of nonclinical development before the official 30-day IND application. Sponsors submit discipline-specific components on a rolling basis through the ESG gateway to their pre-IND, with a Qualified Research Initiative (QRI) reviewing each component and flagging issues that could trigger a clinical hold. FDA will let sponsors and QRIs set the submission sequence and timeline, and sponsors plus QRIs will give written and verbal feedback throughout the pilot, from IND-initiating activities to first-in-human trial initiation, to shape future iterations.
- fda.govPickFDA Expedited Investigational New Drug (IND) Pilot Program
The FDA has launched the Expedited IND Pilot Program under HHS Operation TrialBlazer to test ways of shortening the path from IND-enabling activities to first-in-human trials in the US. Sponsors partnering voluntarily with qualified research institutions, which advise on toxicology, clinical and CMC components, can submit IND pieces for rolling FDA review rather than waiting for a complete package. FDA retains full regulatory authority, and the pilot's evidence may shape future policy such as accreditation of these institutions.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 17 05:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.